164 related articles for article (PubMed ID: 15073030)
1. Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope.
Parker ET; Healey JF; Barrow RT; Craddock HN; Lollar P
Blood; 2004 Aug; 104(3):704-10. PubMed ID: 15073030
[TBL] [Abstract][Full Text] [Related]
2. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII.
Healey JF; Barrow RT; Tamim HM; Lubin IM; Shima M; Scandella D; Lollar P
Blood; 1998 Nov; 92(10):3701-9. PubMed ID: 9808564
[TBL] [Abstract][Full Text] [Related]
3. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules.
Barrow RT; Healey JF; Gailani D; Scandella D; Lollar P
Blood; 2000 Jan; 95(2):564-8. PubMed ID: 10627463
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis.
Lubin IM; Healey JF; Barrow RT; Scandella D; Lollar P
J Biol Chem; 1997 Nov; 272(48):30191-5. PubMed ID: 9374501
[TBL] [Abstract][Full Text] [Related]
5. The humoral response to human factor VIII in hemophilia A mice.
Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
J Thromb Haemost; 2007 Mar; 5(3):512-9. PubMed ID: 17181826
[TBL] [Abstract][Full Text] [Related]
6. Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII.
Lollar P
Thromb Haemost; 1997 Jul; 78(1):647-51. PubMed ID: 9198232
[TBL] [Abstract][Full Text] [Related]
7. New characteristics of anti-factor VIII inhibitor antibody epitopes and unusual immune responses to Factor VIII.
Scandella D
Semin Thromb Hemost; 2002 Jun; 28(3):291-6. PubMed ID: 12098091
[TBL] [Abstract][Full Text] [Related]
8. Epitope mapping of human factor VIII inhibitor antibodies by site-directed mutagenesis of a factor VIII polypeptide.
Ware J; MacDonald MJ; Lo M; de Graaf S; Fulcher CA
Blood Coagul Fibrinolysis; 1992 Dec; 3(6):703-16. PubMed ID: 1283342
[TBL] [Abstract][Full Text] [Related]
9. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
Lei TC; Scott DW
Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
[TBL] [Abstract][Full Text] [Related]
10. Identification of plasma antibody epitopes and gene abnormalities in Japanese hemophilia A patients with factor VIII inhibitor.
Sugihara T; Takahashi I; Kojima T; Okamoto Y; Yamamoto K; Kamiya T; Matsushita T; Saito H
Nagoya J Med Sci; 2000 May; 63(1-2):25-39. PubMed ID: 10911718
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain.
van den Brink EN; Turenhout EA; Bank CM; Fijnvandraat K; Peters M; Voorberg J
Blood; 2000 Jul; 96(2):540-5. PubMed ID: 10887116
[TBL] [Abstract][Full Text] [Related]
12. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.
Kahle J; Orlowski A; Stichel D; Healey JF; Parker ET; Jacquemin M; Krause M; Tiede A; Schwabe D; Lollar P; Königs C
Blood; 2017 Aug; 130(6):808-816. PubMed ID: 28507083
[TBL] [Abstract][Full Text] [Related]
13. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.
Purohit VS; Ramani K; Sarkar R; Kazazian HH; Balasubramanian SV
J Biol Chem; 2005 May; 280(18):17593-600. PubMed ID: 15728582
[TBL] [Abstract][Full Text] [Related]
14. The diversity of the immune response to the A2 domain of human factor VIII.
Markovitz RC; Healey JF; Parker ET; Meeks SL; Lollar P
Blood; 2013 Apr; 121(14):2785-95. PubMed ID: 23349389
[TBL] [Abstract][Full Text] [Related]
15. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A.
Reipert BM; Ahmad RU; Turecek PL; Schwarz HP
Thromb Haemost; 2000 Nov; 84(5):826-32. PubMed ID: 11127864
[TBL] [Abstract][Full Text] [Related]
16. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
[TBL] [Abstract][Full Text] [Related]
17. Antigenicity of putative phospholipid membrane-binding residues in factor VIII.
Barrow RT; Healey JF; Jacquemin MG; Saint-Remy JM; Lollar P
Blood; 2001 Jan; 97(1):169-74. PubMed ID: 11133757
[TBL] [Abstract][Full Text] [Related]
18. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
[TBL] [Abstract][Full Text] [Related]
19. Identification of coagulation factor VIII A2 domain residues forming the binding epitope for low-density lipoprotein receptor-related protein.
Sarafanov AG; Makogonenko EM; Pechik IV; Radtke KP; Khrenov AV; Ananyeva NM; Strickland DK; Saenko EL
Biochemistry; 2006 Feb; 45(6):1829-40. PubMed ID: 16460029
[TBL] [Abstract][Full Text] [Related]
20. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.
Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL
Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
